**EXPLANATORY STATEMENT**

*Therapeutic Goods Act 1989*

*Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Tocilizumab) Instrument 2021*

The *Therapeutic Goods Act 1989* (“the Act”) provides for the establishment and maintenance of a national system of controls for the quality, safety, efficacy and timely availability of therapeutic goods that are used in, or exported from, Australia. The Act also provides for a scheme allowing pharmacists to substitute certain medicine for other medicine if the Minister has declared there is a serious scarcity of the other medicine. The Act is administered by the Therapeutic Goods Administration (“the TGA”) within the Australian Government Department of Health.

Subsection 30EK(1) of the Act provides that the Minister may, by legislative instrument, declare that there is a serious scarcity of specified medicine (“the scarce medicine”) across the whole or a specified part or parts of Australia, and specify the medicine (“the substitutable medicine”) that pharmacists are permitted to dispense in substitution for the scarce medicine and the circumstances in which that substitution is permitted.

Subsection 30EK(2) of the Act provides that the Minister may only make an instrument under subsection 30EK(1) if satisfied that the supply of the scarce medicine in Australia is not currently meeting the demand for that medicine for all of the patients in Australia who take that medicine or, alternatively, there is an imminent risk that supply of the scarce medicine in Australia will not, or will not be likely to, meet the demand for that medicine for all of the patients in Australia who take, or who may need to take, that medicine. In either case, there must be a significant risk of adverse health consequences for patients in Australia if they are not able to take the scarce medicine.

Subsection 30EK(3) of the Act provides that both the scarce medicine and the substitutable medicine must contain one or more substances included in Schedule 4 to the current Poisons Standard (i.e. prescription medicines) and must not contain any substances included in Schedule 8 to the current Poisons Standard (i.e. substances for which particular levels of control are required or recommended in order to avoid abuse, misuse or dependence).

The *Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Tocilizumab) Instrument 2021* (“the Instrument”) is a legislative instrument made under subsection 30EK(1) of the Act. It declares that there is a serious scarcity across Australia of a specified medicine (“the scarce medicine”), specifies the medicine that pharmacists are permitted to dispense in substitution for the scarce medicine (“the substitutable medicine”), and the circumstances in which they may do so.

The Instrument declares two medicines as scarce medicines, ACTEMRA tocilizumab (rch) 162mg/0.9mL solution for injection pre-filled syringe, and ACTEMRA tocilizumab (rch) 162mg/0.9mL solution for injection pre-filled pen, ACTPen Autoinjector, and has the effect that each are specified as being substitutable for the other in the relevant permitted circumstances.

**Background**

Medicine shortages have become an increasing problem in recent years, for a number of reasons, including a decrease in local manufacturing, logistics problems and increases in demand. The TGA receives approximately 105 new medicine shortage notifications every month. The problem of medicine shortages has been amplified as a result of the COVID-19 pandemic.

When a medicine is unavailable, community pharmacists have limited scope to substitute another medicine without the prior approval of the prescribing doctor. A pharmacist may substitute a different brand of an equivalent product, which may include an equivalent overseas-registered medicine approved for supply under section 19A of the Act. However, where there is no such equivalent available, the pharmacist cannot substitute a different medicine. If the pharmacist is unable to contact the prescriber to authorise a change to the prescription, the patient may be unable to obtain their medicine. This impedes timely availability of medicines and risks interruption to treatment, which can impact patient health and also cause anxiety and stress for patients.

During 2020, an informal arrangement was implemented between the Commonwealth and the states and territories to allow pharmacist substitution of medicines that are in shortage, with patient consent. However, this informal arrangement is implemented through state and territory legislation, and some state and territory legislation allows for such provision to be made for pharmacist substitution only during a public health emergency. A need therefore arose for a more consistent and responsive pharmacist substitution scheme to help alleviate the effects of medicine shortages, that does not rely on state and territory legislation and that both allows substitution arrangements to be in place consistently across all states and territories more quickly, and reflects that medicine shortages may occur in a range of circumstances, not only where there is a public health emergency.

The *Therapeutic Goods Amendment (2020 Measures No. 2) Act 2021* (“the Amendment Act”) amended the Act to introduce a pharmacist substitution scheme in Division 2C of Part 3-2 of the Act, with the new provisions commencing on 20 February 2021. Under the scheme, section 30EK of the Act provides for the making of a legislative instrument declaring a serious scarcity and specifying the scarce medicine, substitutable medicine and permitted circumstances. That instrument operates in tandem with section 30EL of the Act, which provides that, where an instrument is in force under subsection 30EK(1) and a pharmacist is authorised to dispense the scarce medicine under a law of a state or territory, then a pharmacist may dispense the substitutable medicine to that person in the circumstances specified in the instrument, despite any law of a state or territory prohibiting substitution.

There are currently shortages, or anticipated to be shortages, across Australia of multiple presentations of medicines containing the active ingredient tocilizumab, due to global demand for these products in connection with the COVID-19 pandemic. The active ingredient tocilizumab is principally used to treat rheumatoid arthritis, giant cell arthritis, systemic juvenile idiopathic arthritis, polyarticular idiopathic arthritis and cytokine release syndrome. Its use in connection with COVID-19 principally relates to administration of intravenous tocilizumab to assist with the treatment of ventilated COVID-19 patients.

Supplies of these medicines for COVID-19 patients are being managed by state and territory health departments and hospitals. The Instrument is not designed to safeguard supplies for this purpose but rather to support access to the limited quantities of the subcutaneous medicines (being, the pre-filled pen and prefilled syringe) that are, or will be, present in pharmacies in Australia for persons in the community who suffer from the other conditions for which these medicines are used, particularly giant cell arthritis or rheumatoid arthritis.

The Instrument identifies two medicines as being scarce medicines across the whole of Australia, and has the effect that each is specified as being substitutable for the other in the circumstances permitted in the Instrument:

* ACTEMRA tocilizumab (rch) 162mg/0.9mL solution for injection pre-filled syringe (registration number 234034); and
* ACTEMRA tocilizumab (rch) 162mg/0.9mL solution for injection pre-filled pen, ACTPen Autoinjector (registration number 296808).

Both medicines contain the active ingredient tocilizumab, and are considered to be safe and effective treatments for the relevant conditions when substituted for each other in the circumstances permitted under the Instrument for each such substitution. These medicines are the same except for the presentation of the medicines (in a pre-filled syringe or pre-filled pen) and method of administration.

The making of the Instrument reflects that, while both of these medicines are the subject of a serious scarcity, small but variable quantities of each are likely to be intermittently available in the market. Allowing pharmacists to substitute one for the other is designed to alleviate the effects of this variability and ensure that patients with the conditions outlined above are able to access suitable treatments without delay. This reduces the risk of interrupted treatment for affected patients, as otherwise patients could not access the substitutable medicine before having a further appointment with their specialist prescriber.

The Instrument specifies a number of specific and general permitted circumstances that have the effect of confining when a pharmacist may substitute each of the substitutable medicines for the relevant scarce medicine for a patient. The circumstances are designed to ensure that there are carefully determined safety-related parameters in place for patients.

The same *specific* permitted circumstances are specified for each substitutable medicine, being that the pharmacist must advise the patient (or person acting on behalf of the patient) to obtain instructions from their prescriber, general practitioner or rheumatology nurse in relation to the administration of the substitutable medicine, and must also advise them of the number of dose units of substitutable medicine that must be taken in substitution for the prescribed dose of scarce medicine. This is based on the dose unit equivalence specified in the Instrument, which provides that one pre-filled pen containing tocilizumab (rch) 162mg/0.9mL solution is equivalent to one pre-filled syringe pen containing tocilizumab (rch) 162mg/0.9mL solution, and vice versa. The patient must also be at least 18 years of age. This reflects a particular concern to ensure that specialist advice is provided for paediatric patients in relation to their treatment.

The same *general* permitted circumstances are also specified for each substitutable medicine including, for example, that the patient (or person acting on behalf of the patient) has evidence of a valid prescription for the scarce medicine unless otherwise permitted by law, and that the prescriber has not indicated on the prescription for the scarce medicine that substitution is not permitted.

In accordance with subsection 30EK(2) of the Act, the rule-maker is satisfied that there is an imminent risk that supplies of each of these medicines will not, or will not be likely to, meet the demand for them for all of the patients in Australia who take, or who may need to take, each of them, and that there is a significant risk of adverse health consequences for patients in Australia if those patients are unable to take the scarce medicine. There are no other matters prescribed by the regulations for the purposes of paragraph 30EK(2)(c).

In accordance with subsection 30EK(3) of the Act, medicines that contain tocilizumab are included in Schedule 4 to the current Poisons Standard, and do not contain a substance in Schedule 8 to the current Poisons Standard.

In accordance with subsection 30EK(5) of the Act, the Instrument specifies the period of time for which it remains in force, being until 31 December 2021, unless sooner revoked. This reflects the period that each of the scare medicines are expected to be the subject of a serious scarcity across Australia. If the shortage of the scarce medicines is resolved sooner or if safety concerns are identified, the Instrument may be revoked before its cessation date.

**Consultation**

The Office of Best Practice Regulation (“OBPR”) has advised that the preparation of a regulation impact statement is not required in relation to the creation of the Instrument as it is unlikely to have more than a minor regulatory impact (OBPR ID 44306).

The TGA has been working closely with stakeholders since the relevant provisions in the Amendment Act commenced in February 2021, and have developed the general permitted circumstances in consultation with these groups. Stakeholders include (but are not limited to) the Australian Medical Association, relevant clinical professional colleges and societies, sponsor peak bodies, wholesalers, state and territory Chief Pharmacists, and pharmacy and pharmacist peak bodies.

In developing this Instrument, the TGA has consulted with the Australian Rheumatology Association, the Australian Medical Association, the Royal Australian College of General Practitioners, state and territory Chief Pharmacists, the Pharmaceutical Society of Australia, the Society of Hospital Pharmacists of Australia, the Pharmacy Guild of Australia, the Pharmacy Board of Australia, and Arthritis Australia to ensure the substitution protocol and associated permitted circumstances are appropriate. The TGA has also consulted with the sponsor of the substitutable medicines to ensure that sufficient supplies of each substitutable medicine are or will be available, although the quantities of each may vary across Australia.

Details of the Instrument are set out in **Attachment A**.

The Instrument is compatible with human rights and freedoms recognised or declared under section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*. A full statement of compatibility is set out in **Attachment B.**

The Instrument is a disallowable legislative instrumentfor the purposes of the *Legislation Act 2003* and commences on the day after it is registered on the Federal Register of Legislation.

**Attachment A**

**Details of the *Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Tocilizumab) Instrument 2021***

**Section 1 – Name**

This section provides that the name of the instrument is the *Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Tocilizumab) Instrument 2021* (“the Instrument”).

**Section 2 – Commencement**

This section provides that the Instrument commences on the day after it is registered on the Federal Register of Legislation.

**Section 3 – Authority**

This section provides that the legislative authority for making the Instrument is section 30EK of the *Therapeutic Goods Act 1989* (“the Act”)*.*

**Section 4 – Definitions**

This section provides the definition of terms used in the Instrument, including ‘pharmacist’ and ‘prescriber’. This section also notes that some expressions used in the Instrument, for example, ‘Register’ and ‘medicine’, have the same meaning as in the Act.

**Section 5 – Declaration of serious scarcity of medicine**

This section provides a declaration that a serious scarcity of the medicine specified in column 2 of each item in the tables in Part 1 and Part 2 of Schedule 1, exists across the whole of Australia.

**Section 6 – Substitution of scarce medicine by pharmacists**

This section provides that, for each item in the tables in Part 1 and Part 2 of Schedule 1, the medicine specified in column 3 is a substitutable medicine that may be dispensed by a pharmacist in substitution for the scarce medicine specified in column 2, in the circumstances specified in column 5 of that item (the specific permitted circumstances) and in the table in Schedule 2 (the general permitted circumstances).

**Section 7 – Period instrument in force**

This section provides that the Instrument remains in force until 31 December 2021.

**Schedule 1─Scarce medicine, substitutable medicine, dose substitution and specific permitted circumstances**

This Schedule specifies the scarce medicines, substitutable medicines and specific permitted circumstances for the purpose of sections 5 and 6.

Columns 2 and 3 of the table in Part 1 of Schedule 1 specify ACTEMRA tocilizumab (rch) 162mg/0.9mL solution for injection pre-filled syringe, Australian Register of Therapeutic Goods (“ARTG”) registration number 234034, as the scarce medicine under that Part, with ACTEMRA tocilizumab (rch) 162mg/0.9mL solution for injection pre-filled pen, ACTPen Autoinjector, ARTG registration number 296808, as the corresponding substitutable medicine.

Columns 2 and 3 of the table in Part 2 of Schedule 1 specify ACTEMRA tocilizumab (rch) 162mg/0.9mL solution for injection pre-filled pen, ACTPen Autoinjector, ARTG registration number 296808, as the scarce medicine under that Part, with ACTEMRA tocilizumab (rch) 162mg/0.9mL solution for injection pre-filled syringe, ARTG registration number 234034 as the corresponding substitutable medicine.

Column 4 of the tables in Part 1 and Part 2 of Schedule 1 specifies the equivalent dose of each scarce medicine and substitutable medicine for the purposes of the permitted circumstances in column 5 of the two tables.

Column 5 of the tables in Part 1 and Part 2 of Schedule 1 sets out the same specific permitted circumstances for each of the substitutable medicines, being that the patient is at least 18 years of age and that the pharmacist must advise the patient (or person acting on behalf of the patient):

* to obtain instructions from their prescriber, general practitioner or rheumatology nurse in relation to the administration of the substitutable medicine; and
* of the number of dose units of substitutable medicine that must be taken by the patient in substitution for the prescribed dose of scarce medicine, based on the dose unit equivalence specified in the Instrument (i.e. that one pre-filled pen containing tocilizumab (rch) 162mg/0.9mL solution is equivalent to one pre-filled syringe pen containing tocilizumab (rch) 162mg/0.9mL solution, and vice versa).

**Schedule 2─General permitted circumstances**

This Schedule specifies the general permitted circumstances in which a substitution of medicine may occur. For the purpose of section 6, substitution may only occur where these circumstances exist.

The general permitted circumstances prescribed are as follows:

1. the patient, or person acting on behalf of the patient, has evidence of a valid prescription for the scarce medicine, unless otherwise permitted by law, i.e. there must be evidence of a prescription for the scarce medicine, which authorises the pharmacist to dispense the scarce medicine (if it were available) to the patient;
2. the pharmacist does not have access to the scarce medicine, i.e. the pharmacist must only substitute a medicine if the scarce medicine is not available to the pharmacist;
3. the prescriber has not indicated on the prescription for the scarce medicine that substitution is not permitted, i.e. if the prescriber has indicated on the prescription that substitution is not permitted, the pharmacist must not dispense the substitutable medicine as this may pose a significant safety risk to the patient. If a prescriber has indicated that substitution, even with a generic product, is not suitable then the substitutable medicine must not be dispensed;
4. the pharmacist has exercised professional judgement and determined that the patient is suitable to receive the substitutable medicine. This requires the pharmacist to exercise professional judgement in relation to the particular patient and their circumstances to assess whether substitution is appropriate for the particular patient. For example, if the pharmacist is of the view that the patient will not be able to use the pre-filled pen or the pre-filled syringe, then the pharmacist must not dispense the substitutable medicine for the patient;
5. the amount of substitutable medicine dispensed would result in the patient receiving sufficient medicine to ensure an equivalent dosage regimen and duration to that prescribed in relation to the scarce medicine. This is to ensure the pharmacist dispenses enough of the substitutable medicine to provide the patient with an equivalent treatment regimen (dosage and duration) as the scarce medicine;
6. the patient, or person acting on behalf of the patient, has consented to receiving the substitutable medicine. If a person does not wish to receive the substitutable medicine, then the pharmacist must not dispense the substitutable medicine;
7. the pharmacist makes a record of dispensing the substitutable medicine in substitution of the scarce medicine at the time of dispensing. This is to ensure that there is a record of the medicine that was actually dispensed to a patient, in case any safety concerns arise;
8. the pharmacist has an established procedure to notify the prescriber of the substitution at the time of, or as soon as practical after, dispensing the substitutable medicine. There are strong safety reasons for ensuring that the prescriber is aware of the particular medicine that has been dispensed to their patient. The prescriber would otherwise assume that the patient was dispensed the prescribed medicine and would not know about the substitution without notice of this from the dispensing pharmacist.

**Attachment B**

**Statement of Compatibility with Human Rights**

*Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011*

***Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Tocilizumab) Instrument 2021***

This disallowable legislative instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

**Overview of legislative instrument**

The *Therapeutic Goods (Serious Scarcity and Substitutable Medicine) (Tocilizumab) Instrument 2021* (“the instrument”) is a legislative instrument made under subsection 30EK(1) of the Act. It declares that there is a serious scarcity across Australia of a specified medicine, specifies the medicine that pharmacists are permitted to dispense in substitution for the scarce medicine, and the circumstances in which they may do so.

Subsection 30EK(1) of the Act provides that the Minister may, by legislative instrument, declare that there is a serious scarcity of specified medicine (“the scarce medicine”) across the whole or a specified part or parts of Australia, and specify the medicine (“the substitutable medicine”) that pharmacists are permitted to dispense in substitution for the scarce medicine and the circumstances in which that substitution is permitted. The effect of an instrument under subsection 30EK(1) is that, pursuant to section 30EL of the Act, a pharmacist is authorised to dispense the substitutable medicine to a person in substitution for the scarce medicine despite any law of a state or territory that may prohibit such substitution, provided that the substitution is in accordance with the circumstances specified in the instrument under subsection 30EK(1).

Medicine shortages have become an increasing problem in recent years for a number of reasons, including a decrease in local manufacturing, logistics problems and increases in demand. The Therapeutic Goods Administration receives notifications of approximately 105 new medicine shortages every month. The problem of medicines shortages has been amplified as a result of the COVID-19 pandemic.

An informal arrangement has been in place between the Commonwealth and the states and territories to allow pharmacist substitution of medicines that are in shortage, with patient consent. However, this informal arrangement is implemented through state and territory legislation, and some state and territory legislation allows for such provision to be made for pharmacist substitution but only during a public health emergency. A need therefore arose for a more streamlined, responsive pharmacist substitution scheme to help alleviate the effects of medicines shortages, that does not rely on state and territory legislation and that both allows substitution arrangements to be in place in a more streamlined fashion and more quickly, and reflects that medicine shortages may occur in a range of circumstances not only where there is a public health emergency.

The *Therapeutic Goods Amendment (2020 Measures No. 2) Act 2021* amended the Act to introduce such a scheme in Division 2C of Part 3-2 of the Act. Section 30EK of the Act provides for the making of an instrument declaring a serious scarcity and specifying the scarce medicine, substitutable medicine and permitted circumstances.

The purpose of the instrument is to declare that there is a serious scarcity across Australia of two medicines, with the effect that each is specified as being substitutable for the other in the circumstances permitted in the instrument:

* ACTEMRA tocilizumab (rch) 162mg/0.9mL solution for injection pre-filled syringe; and
* ACTEMRA tocilizumab (rch) 162mg/0.9mL solution for injection pre-filled pen, ACTPen Autoinjector.

There are currently shortages, or anticipated to be shortages, across Australia of multiple presentations of medicines containing the active ingredient tocilizumab, due to global demand for these products in connection with the COVID-19 pandemic.

The active ingredient tocilizumab is principally used to treat rheumatoid arthritis, giant cell arthritis, systemic juvenile idiopathic arthritis, polyarticular idiopathic arthritis and cytokine release syndrome. Its use in connection with COVID-19 principally relates to assisting with the treatment of severe COVID-19 and mitigating the effects of a patient’s immune system experiencing a cytokine storm following infection.

Supplies of these medicines for COVID-19 patients are being managed by state and territory health departments and hospitals. The instrument is not designed to safeguard supplies for this purpose but rather to support access to the limited quantities of these medicines that are, or will be, present in pharmacies in Australia for persons in the community who suffer from the other conditions for which these medicines are used, particularly giant cell arthritis or rheumatoid arthritis.

Both medicines contain the active ingredient tocilizumab, and are considered to be safe and effective treatments for the relevant conditions when substituted for each other in the circumstances permitted under the instrument for each such substitution.

The making of the instrument reflects that, while both of these medicines are the subject of a serious scarcity, small but variable quantities of each are likely to be intermittently available in the market. Allowing pharmacists to substitute one for the other is designed to alleviate the effects of this variability and ensure that patients with the conditions outlined above are able to access suitable treatments without delay. This reduces the risk of interrupted treatment for affected patients. which would otherwise occur if patients could not access the substitutable medicine before having a further appointment with their specialist prescriber.

The instrument specifies a number of specific and general permitted circumstances that have the effect of confining when a pharmacist may substitute each of the substitutable medicines for the relevant scarce medicine for a patient. The circumstances are designed to reflect carefully determined safety-related parameters and include, for example, that the patient is at least 18 years of age and that the pharmacist must advise the patient (or person acting on behalf of the patient) to obtain instructions from their prescriber, general practitioner or rheumatology nurse on the administration of the substitutable medicine (this is an example of a specific permitted circumstance), and the patient (or person acting on behalf of the patient) has evidence of a valid prescription for the scarce medicine unless otherwise permitted by law (this is an example of a general permitted circumstance).

The instrument specifies the period of time for which it remains in force, being until 31 December 2021, unless sooner revoked. This reflects the period that each of the scare medicines are expected to be the subject of a serious scarcity across Australia. If the shortage of the scarce medicines is resolved sooner or if safety concerns are identified, the instrument may be revoked before its cessation date.

**Human rights implications**

The instrument engages the right to health in Article 12 of the International Covenant on Economic, Social and Cultural rights (“the ICESCR”).Article 12 of the ICESCR promotes the right of all individuals to enjoy the highest attainable standards of physical and mental health, and includes an obligation to take reasonable measures within available resources to progressively secure broader enjoyment of the right.

In *General Comment No. 14: The Right to the Highest Attainable Standard of Health (Art. 12)* (2000), the United Nations Committee on Economic, Social and Cultural Rights states that health is a ‘fundamental human right indispensable for the exercise of other human rights’, and that the right to health is not to be understood as the right to be healthy, but includes the right to a system of health protection which provides equal opportunity for people to enjoy the highest attainable level of health.

The instrument takes positive steps to promote the right to health by facilitating improved access to the substitutable medicines, each of which are also scarce medicines under the instrument and able to be used as an alternative medicine for the other, and to ameliorate the effects of their uneven availability across the Australian market. By enabling pharmacists to substitute these important products, the instrument will support the right to health through helping Australian patients avoid the suffering that may otherwise occur due to an interruption in treatment for their conditions such as giant cell arthritis or rheumatoid arthritis.

**Conclusion**

This legislative instrument is compatible with human rights because it promotes the right to health in Article 12 of the ICESCR and otherwise does not raise any other human rights issues.